PA
SCLN

Parallel Advisors’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History

Parallel Advisors’s Portfolio SCLN Stock Details SCLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-7,000
Closed -$77K – 2332
2017
Q2 		$77K Hold
7,000
– – 0.01% 559
2017
Q1 		$68K Hold
7,000
– – 0.01% 568
2016
Q4 		$76K Buy
+7,000
New +$70K 0.02% 458

Other funds holding SCLN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
GP
GLG Partners London, United Kingdom $2.14B AUM 21.14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
MWNA
Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Parallel Advisors's SCLN Position: Q3 2017 in Review

Parallel Advisors sold out of Sciclone Pharmaceuticals Inc (SCLN) in Q3 2017, closing a stake of 7,000 shares — an estimated $77K sold.

Parallel Advisors first reported a position in SCLN in Q4 2016 and held it in 3 quarters. The position peaked at $77K in Q2 2017. 129 funds tracked by Wall St. Rank hold SCLN as of Q3 2017.

  • Parallel Advisors reported no remaining Sciclone Pharmaceuticals Inc position as of Q3 2017 after selling out during the quarter.
  • Parallel Advisors sold 7,000 Sciclone Pharmaceuticals Inc shares in Q3 2017, an estimated $77K.
  • Parallel Advisors first reported a position in Sciclone Pharmaceuticals Inc in Q4 2016 and held it in 3 quarters.
  • Parallel Advisors's Sciclone Pharmaceuticals Inc position peaked at $77K in Q2 2017.
  • 129 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q3 2017.

Based on Parallel Advisors's 13F filing for Q3 2017, filed 14 Nov 2017.